<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02134054</url>
  </required_header>
  <id_info>
    <org_study_id>SUSI-CS_1</org_study_id>
    <nct_id>NCT02134054</nct_id>
  </id_info>
  <brief_title>Stavanger IBD Study - Cross Sectional</brief_title>
  <acronym>SUSI-CS</acronym>
  <official_title>Stavanger University Hospital IBD Study - a Cross Sectional Longitudinal Study on Patients Treated With Biologics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rikshospitalet University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helse Stavanger HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this cross sectional and longitudinal study, patients with inflammatory bowel disease on&#xD;
      biological treatment with infliximab or adalimumab will be included.&#xD;
&#xD;
      After inclusion, the dosage of their existing biological therapy will be adjusted following&#xD;
      regular trough-level and antibody-level monitoring, according to a treatment algorithm.&#xD;
&#xD;
      Disease activity markers, fatigue and QoL will be assessed during the study. The hypothesis&#xD;
      is that therapeutic drug monitoring may improve clinical disease outcome after one year of&#xD;
      follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical remission rate</measure>
    <time_frame>One Year</time_frame>
    <description>Harvey Bradshaw Index &lt;5 Partial Mayo score &lt;=2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom scoring</measure>
    <time_frame>One Year</time_frame>
    <description>Harvey Bradshaw Index, Partial Mayo Score. Change after therapeutic drug monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>One year</time_frame>
    <description>C reactive protein, Fecal Calprotectin. Change after therapeutic drug monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue scoring</measure>
    <time_frame>One Year</time_frame>
    <description>Assessed by Fatigue severity scale and Visual analogue scale. Change after therapeutic drug monitoring.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Healthcare resource utilization</measure>
    <time_frame>One year</time_frame>
    <description>Registration of&#xD;
Outpatient visits&#xD;
Hospital admissions (days)&#xD;
Sick leave (days)&#xD;
Visits at general practitioner due to IBD activity&#xD;
Endoscopy due to IBD activity</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">210</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Biologic</arm_group_label>
    <description>Patients on treatment with biologics (infliximab or adalimumab)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Standard blood sampling Serum sampling - trough/antibodies of biological agent&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with inflammatory bowel disease established (minimum 3 doses) on treatment with&#xD;
        infliximab or adalimumab&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with inflammatory bowel disease on treatment with infliximab or&#xD;
             adalimumab of any duration (at least 3 doses)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to consent&#xD;
&#xD;
          -  Inability to adhere to treatment protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tore B Grimstad, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stavanger University Hospital, Department of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 29, 2014</study_first_submitted>
  <study_first_submitted_qc>May 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2014</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Therapeutic drug monitoring</keyword>
  <keyword>Biological treatment</keyword>
  <keyword>IBD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

